To that end, the objective of this study was to report the long-term clinical outcomes in a large, single-institution cohort of patients with pathogenic BRCA1/2 variants who chose BCT after initial diagnosis of breast cancer, with stratification of outcomes by BRCA variant type to help inform patients with a variant in either gene. This evidence concerns the gene BRCA1 and breast cancer.